Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Delisting risk
confidence 98%
filed 2026-07-06
The filing discloses Item 3.01 notification that CISO Global's common stock failed to meet Nasdaq's minimum bid price requirement of $1.00 per share for 30 consecutive business days. While the company received a second 180-day compliance period (until December 28, 2026) and is currently still listed, the filing explicitly warns that "if compliance cannot be demonstrated by December 28, 2026, Staff will provide written notification that the common stock will be delisted." This is a material delisting risk event that would significantly affect investor assessment of the registrant's continued exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-06
Item 3.01
Polar Power received a deficiency letter from Nasdaq on May 1, 2026, for failing to comply with Listing Rule 5550(b) due to reporting only $144,000 in stockholders' equity. Although the company received a compliance extension until October 28, 2026, the filing explicitly states that failure to evidence compliance by that date or upon filing its 2026 periodic report "may be subject to delisting," with Nasdaq providing written notification of delisting if terms are not satisfied. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-02
Item 8.01
Barinthus Biotherapeutics received notice from Nasdaq on June 30, 2026, granting an additional 180-calendar-day compliance period (until December 28, 2026) to regain compliance with the $1.00 minimum bid price requirement after its ADSs were transferred from the Nasdaq Global Market to the Nasdaq Capital Market. If compliance is not regained by the deadline, Nasdaq will issue notice of delisting.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-02
Item 3.01
MV Oil Trust's net profits interest terminated on June 30, 2026, triggering dissolution of the Trust. The trustee notified the NYSE on July 2, 2026 of the Trust's intention to voluntarily withdraw listing, with delisting expected prior to market open on July 27, 2026, followed by Form 15 deregistration.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-02
The Company discloses receipt of a Nasdaq compliance notice on March 26, 2026, for failure to meet the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)), and now reports on July 1, 2026, that it has regained compliance after the closing bid price remained at $1.00 or greater for 10 consecutive business days. This is a material delisting-risk disclosure: the Company faced potential delisting but has now cured the deficiency. The resolution is favorable, but the prior non-compliance and the regulatory process itself are material to investors assessing listing status and trading risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-02
Item 8.01
CID Holdco disclosed ongoing Nasdaq continued listing compliance deficiencies regarding minimum market value of listed securities ($50 million) and minimum market value of publicly held shares ($15 million), despite regaining compliance with the Bid Price Requirement as of June 23, 2026.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-02
Item 3.01
HeartBeam received a deficiency notice from Nasdaq on June 30, 2026, for failure to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The Company has been given a 180-day compliance period (until December 28, 2026) to regain compliance, with the explicit warning that failure to do so will result in delisting notice. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-02
EX-99.1
MDxHealth received a Nasdaq notification dated June 30, 2026, that it has failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until December 28, 2026) to regain compliance or faces potential delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting investor assessment of the company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-02
The filing discloses two material events: (1) completion of the Mortgage One Group acquisition (Item 2.01, ma_activity), and (2) a Nasdaq delisting notice due to failure to maintain the $1.00 minimum bid price for 30 consecutive business days (Item 3.01, delisting_risk). While both are material, the delisting notice is the more urgent and existential threat to the registrant. The company has 180 days to regain compliance or faces delisting, with explicit language that "there can be no assurance that the Company will be able to regain or maintain compliance." This is a terminal listing risk that would materially affect investor assessment.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-02
RenovoRx received notification on July 1, 2026, that while it has not regained compliance with Nasdaq's $1.00 minimum bid price requirement, it has been granted an additional 180-calendar-day compliance period until December 28, 2026. The filing explicitly states that failure to comply by that date will result in delisting notification. This is a classic delisting-risk disclosure under Item 3.01, indicating substantial jeopardy to the company's continued listing on Nasdaq Capital Market.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-02
The filing's primary disclosure is Nasdaq's determination to delist Snail's Class A Common Stock from The Nasdaq Capital Market (Item 3.01), issued pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii) due to failure to maintain the $1.00 minimum bid price requirement and non-compliance with continued listing standards. While the company announced a 1-for-5 reverse stock split as a remedial measure, the core event is the delisting notice and the company's stated intent to appeal. This is a terminal threat to the registrant's listing status and is highly material to investors.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-02
AI Financial Corporation received a Nasdaq notification on July 1, 2026, that it failed to maintain the minimum closing bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days. The company has 180 calendar days (until December 28, 2026) to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-02
The filing discloses a written notice from Nasdaq on June 29, 2026, that Callan JMB Inc. has failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The Company has been granted a 180-day compliance period (until December 28, 2026) to regain compliance, with potential delisting if it fails to do so. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-02
Item 3.01
FingerMotion received a deficiency letter from Nasdaq on June 30, 2026, notifying the company that its stock price has fallen below the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The company has 180 calendar days until December 28, 2026, to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-02
Item 3.01
Boxlight received written notice from Nasdaq on July 1, 2026, that its securities are subject to suspension and delisting due to non-compliance with the $2.5 million stockholders' equity requirement under Nasdaq Listing Rule 5550(b). The company plans to request a hearing before the Nasdaq Hearings Panel but acknowledges "there can be no assurance that the Panel will grant the Company's request for continued listing." This is a direct delisting notice triggering Item 3.01 disclosure and represents a material threat to the company's continued public trading status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-02
The 6-K discloses that Nasdaq has granted Integrated Media Technology Limited an additional 180-day cure period (until December 29, 2026) to regain compliance with the minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2). The company failed to regain compliance during the initial 180-day period (which ended June 29, 2026) and now faces a material delisting risk if it cannot achieve ten consecutive business days at or above $1 per share during the extended period. This is a classic delisting-risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-01
Item 3.01
Stratus Properties has voluntarily delisted its common stock from Nasdaq effective August 10, 2026, and intends to deregister with the SEC via Form 15 filing, suspending all Exchange Act reporting obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-01
Item 3.01
TopBuild's common stock (ticker BLD) was delisted from NYSE effective July 1, 2026, following completion of the merger with QXO; NYSE filed Form 25 to initiate deregistration under Section 12(b) of the Exchange Act, and TopBuild intends to file Form 15 to deregister under Section 12(g) and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-01
Item 3.01
ExxonMobil Common Stock will be delisted from the NYSE following completion of the Redomiciliation Merger, with trading suspension on July 1, 2026 and expected delisting via Form 25 filing. The original ExxonMobil Common Stock will be replaced by ExxonMobil Holdings Corporation Common Stock trading under the same ticker.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-01
The Company's Board approved a reverse stock split (1-for-15) effective July 6, 2026, explicitly stated as intended to "regain compliance with the Nasdaq $1.00 minimum bid price requirement." This disclosure indicates the Company had fallen below the minimum bid price threshold and faces delisting risk absent the reverse split. The timing and stated purpose directly signal a continued listing compliance issue.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-01
Item 3.01
The NYSE notified ESS Tech on June 30, 2026, and publicly announced on July 1, 2026, that it has determined to commence delisting proceedings for the Company's Public Warrants (trading under symbol "GWH.W") and immediately suspended trading due to "abnormally low" trading price levels pursuant to NYSE Listed Company Manual Section 802.01D. This is a direct notice of delisting action and suspension, which is the core disclosure required under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-30
EX-99.1
LightInTheBox announced on June 26, 2026 that it has regained compliance with NYSE continued listing standards under Section 802.01B after receiving a "below criteria" notice on December 26, 2024 due to insufficient market capitalization and stockholders' equity. The company was granted an 18-month cure period on May 13, 2025, and has now demonstrated compliance. This is a material delisting-risk resolution—the company was previously at risk of delisting and has now cured the deficiency.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-30
EX-99.1
XCharge received a written notice from Nasdaq on June 24, 2026, that it failed to meet the minimum bid price requirement (closing bid price below $1.00 per ADS for 30 consecutive business days). The company has 180 calendar days until December 21, 2026, to regain compliance, and if it fails to do so, Nasdaq will provide notice of delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 90%
filed 2026-06-30
Item 5.03
Interactive Strength announced a 1-for-7 reverse stock split effective June 29, 2026, undertaken to regain compliance with the Nasdaq Capital Market's minimum bid price requirement of $1.00 per share and maintain its continued listing status. The reverse split was approved by stockholders on June 8, 2026 and finalized by the board on June 18, 2026 via charter amendment.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-30
Item 3.01
Gulf Resources received a notice from Nasdaq on June 25, 2026 accepting a compliance plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) following delinquency notifications for failure to timely file its Form 10-K and Form 10-Q. The filing explicitly states that if the Company fails to evidence compliance upon filing the delinquent reports, "Staff will notify the Company that its securities will be subject to delisting." This is a classic delisting-risk disclosure under Item 3.01, with material consequences for continued trading on Nasdaq.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-30
EX-99.1
The press release announces that Wetour Robotics has regained compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)) after receiving a deficiency notice on December 30, 2025. While the announcement is positive (compliance regained), the underlying event—the prior non-compliance and delisting risk—is material to investors. The disclosure explicitly references the deficiency letter, the 180-day compliance period, and the closure of the matter, which are hallmarks of delisting-risk disclosures under Item 3.01. The company's ability to maintain Nasdaq listing standards is a material concern flagged in the forward-looking statements.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-30
The filing discloses that HCW Biologics regained compliance with Nasdaq's Bid Price Rule (Listing Rule 5550(a)(2)) following a prior non-compliance notice, but remains subject to a mandatory Panel Monitor through June 17, 2027. Critically, the Panel's decision imposes a conditional delisting threat: if the Company falls out of compliance with the Bid Price Rule again during the monitoring period, it will receive an immediate Delist Determination Letter without opportunity for a cure period or compliance plan. This is a material delisting risk disclosure under Item 3.01, as the Company's continued listing is now contingent on maintaining compliance under heightened scrutiny.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-30
The filing discloses that Nasdaq previously notified the Company on January 12, 2026, of non-compliance with the $1.00 minimum bid price requirement for continued listing, with a compliance deadline of July 13, 2026. The June 30, 2026 notice confirms the Company has regained compliance and the matter is closed. This is a material delisting-risk event—the Company faced a concrete threat of delisting but successfully remedied the violation before the deadline.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-30
The filing discloses a June 24, 2026 notice from NYSE American indicating InnSuites Hospitality Trust is not in compliance with continued listing standards under Section 1003(a)(i), citing a stockholders' deficit of approximately $(921,921) as of April 30, 2026 and losses in two of three most recent fiscal years. The Trust must submit a compliance plan by July 24, 2026 to regain compliance by December 24, 2027, or face delisting proceedings. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-30
Item 3.01
SolarMax received a formal notice from Nasdaq on June 22, 2026, that it fails to meet the continued listing requirement under Rule 5550(b)(2) due to insufficient market value of listed securities (below the $35 million minimum). The company has a 180-day compliance period expiring December 21, 2026, and faces delisting if it does not regain compliance. This is a direct delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 75%
filed 2026-06-29
EX-99.1
New Found Gold announces conditional approval to graduate from the TSX Venture Exchange to the Toronto Stock Exchange, with concurrent delisting from TSXV. While this is a positive corporate milestone reflecting the company's maturation, the delisting from TSXV is a material change in listing status. The disclosure explicitly states "Concurrently with the graduation to the TSX, the Company's common shares will be delisted from the TSXV," which constitutes a transfer of listing venue (Item 3.01 equivalent). This affects trading venue and liquidity for shareholders, making it material to investor assessment.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-29
The filing discloses that T1 Energy's publicly traded warrants will expire on July 9, 2026, cease trading on the NYSE under symbol "TE WS" before market open that day, and the NYSE intends to file a Form 25 with the SEC to effect delisting and deregistration of the Public Warrants under Section 12(b) of the Securities Exchange Act. This is a material delisting event affecting the warrant securities, though the Common Stock will continue trading under "TE."
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-29
EX-99.1
The Company received a Nasdaq notification letter on June 26, 2026, stating it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) because the closing bid price was below $1.00 per share for 30 consecutive business days. The Company has 180 calendar days until December 23, 2026, to regain compliance, or it may face delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 75%
filed 2026-06-29
Braskem discloses that Fitch Ratings and S&P Global Ratings have downgraded the Company's corporate credit rating to C and D respectively, in connection with a Precautionary Injunctive Relief proceeding. These are distressed-level credit ratings that signal severe financial stress and heightened delisting risk. While the filing does not explicitly mention delisting, the combination of emergency legal proceedings and catastrophic credit downgrades to near-default levels creates material delisting risk under NYSE continued listing standards.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 85%
filed 2026-06-29
EX-99.1
The exhibit announces restoration of trading in trivago ADRs on German stock exchanges following a suspension that began November 17, 2023. While the announcement is positive (trading has resumed), it discloses a material delisting/trading suspension event and its resolution. The suspension resulted from Clearstream's refusal to issue a settlement declaration due to an ISIN change associated with an ADS ratio change. This is a material event affecting the registrant's listing status and investor access to trading venues, even though the immediate disclosure is of restoration rather than continued suspension.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-26
Item 3.01
The filing discloses a delisting notice under Item 3.01. Although the Company ultimately regained compliance with Nasdaq's minimum bid price rule (Listing Rule 5550(a)(2)) and the delisting matter is now closed as of June 26, 2026, the disclosure documents the Company's prior failure to maintain the $1.00 minimum bid price for 30 consecutive business days (triggering the February 18, 2026 delisting notice) and its subsequent remediation. This is a material event affecting the registrant's listing status and investor confidence, even though the immediate delisting risk has been resolved.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-26
Item 3.01
ProAssurance notified the NYSE on June 26, 2026 of the completion of the merger and requested suspension of trading and delisting of its common stock from the NYSE via Form 25 filing. The company intends to file Form 15 to terminate registration under Section 12(g) and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-26
Item 8.01
The filing discloses a Nasdaq listing compliance violation under Rule 5250(c)(1) due to failure to timely file the Form 10-K and subsequently the Form 10-Q. Although the Company ultimately cured the deficiency by filing the Form 10-Q on June 17, 2026, and Nasdaq confirmed compliance on June 23, 2026, the disclosure of the non-compliance notice and the risk of delisting that preceded the cure is material to investors. The Company's initial failure to meet continued listing standards represents a delisting risk event, even though it was subsequently resolved.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-06-26
EX-99.1
TNL Mediagene received a Nasdaq staff determination letter on June 22, 2026, notifying the company that its securities are subject to delisting from The Nasdaq Capital Market due to two separate violations: (1) closing bid price below $1.00 per share for 30 consecutive business days, and (2) failure to meet the $2,500,000 minimum stockholders' equity requirement. The company is ineligible for a compliance period due to a prior reverse stock split. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially threatening the company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-26
Item 3.01
Nasdaq notified Upexi on June 24, 2026, that the Company is not in compliance with Nasdaq Listing Rule 5635(a) due to two convertible note issuances totaling approximately $187 million that were convertible into 20% or more of pre-transaction shares without required shareholder approval. The Company has 45 days to submit a compliance plan or face potential delisting proceedings.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-26
EX-99.1
Orion Digital received a Nasdaq notification on June 25, 2026, that its common shares have closed below the minimum US$1.00 per share requirement for continued listing under Nasdaq Listing Rule 5550(a)(2). The company has been given 180 calendar days (until December 22, 2026) to regain compliance. This is a classic delisting-risk disclosure: the registrant has failed to satisfy a continued listing rule and faces potential delisting if it does not remedy the deficiency within the specified compliance period.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-26
HCW Biologics disclosed a 1-for-6 reverse stock split effectuated in direct response to a Nasdaq Hearings Panel decision letter (May 29, 2026) that threatened "automatic delisting" if the company failed to maintain compliance with the Bid Price Rule (minimum $1.00 per share) prior to September 22, 2026. The filing explicitly states the reverse split was "intended to ensure compliance with the Bid Price Rule as well as other conditions required by the Panel" to avoid immediate delisting. This is a material disclosure of delisting risk and the company's remedial action to address it.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-26
The filing discloses that Matinas BioPharma received notice on June 24, 2026 from NYSE American of non-compliance with continued listing standards under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide, citing stockholders' equity of $3.02 million (below the $4.0 million minimum) and losses in five consecutive fiscal years. While the company's plan to regain compliance was accepted with a deadline of October 2, 2027, the filing explicitly warns that "if the Company does not regain compliance...then NYSE American staff may initiate delisting proceedings as appropriate." This is a material delisting risk event that would significantly affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-06-25
The NYSE notified the Company on June 24, 2026 of its determination to commence delisting proceedings for the Company's warrants (LANV-WT) due to "abnormally low selling price" pursuant to NYSE Listed Company Manual Section 802.01D. Trading in the warrants has been suspended immediately, and the NYSE will apply to the SEC to delist the warrants. This is a direct notice of delisting action, matching the delisting_risk category.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-25
Item 3.01
Heron Therapeutics received a written notice from Nasdaq on June 25, 2026, that its common shares failed to meet the minimum $1.00 per share bid price requirement for continued listing on The Nasdaq Capital Market. The company has been granted a 180-day compliance period (until December 22, 2026) to cure the deficiency, with potential for an additional 180-day period if certain conditions are met. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued market access.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-25
EX-99.1
IceCure announced on June 25, 2026, that it has regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)) after the closing bid price reached $1.00 or greater for 10 consecutive business days. This disclosure directly addresses a delisting risk — the company had previously fallen below the $1.00 minimum bid price threshold and faced potential delisting, but has now cured that deficiency. The announcement explicitly states "Nasdaq considers the bid price deficiency matter now closed," confirming resolution of a material listing compliance issue.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-25
Item 8.01
Rocket One received formal notification from Nasdaq on June 24, 2026, confirming that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), resolving a prior delisting risk. The disclosure explicitly states "the matter is now closed," indicating resolution of a compliance deficiency that previously threatened continued listing. This is material because it directly addresses the registrant's ability to maintain its public market listing.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-25
The filing discloses Item 3.01 regarding Nasdaq listing compliance. The Company received notice on May 21, 2026 for failure to timely file its Form 10-Q and on April 16, 2026 for failure to timely file its Form 10-K, both violations of Nasdaq Listing Rule 5250(c)(1). Although the Company subsequently filed the Form 10-Q on June 22, 2026 and regained compliance as of June 24, 2026, the disclosure of prior delisting risk and the regulatory process itself constitutes a material event affecting investor assessment of the registrant's operational and compliance standing.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-25
Item 8.01
Nasdaq notified the Company that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Form 10-Q, resolving a prior delinquency in timely filing of periodic reports that had threatened the Company's continued listing.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-25
The 6-K discloses that WF International has regained compliance with Nasdaq Listing Rule 5550(a)(2) after a prior deficiency notice on December 24, 2025 for failing to maintain the $1.00 minimum bid price for 30 consecutive business days. While the company has now cured the deficiency, the disclosure of the prior non-compliance and the 180-day cure period granted (until June 22, 2026) constitutes a material delisting risk event that would have affected investor assessment during the compliance period. The resolution of this matter is material to investors monitoring the company's continued listing status.
View raw filing on EDGAR →